{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-000356","form_type":"8-K","ticker":"PTHS","cik":"0001919246","company_name":"Pelthos Therapeutics Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.310723+00:00","generated_at":"2026-06-05T21:01:21.600706+00:00","sec_items":["1.01","3.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Chromocell Therapeutics prices IPO at $6.00/share, raises $6.6M gross, lists on NYSE American","bullets":["Sold 1,100,000 shares at $6.00; gross proceeds ~$6.6M; closed Feb 21, 2024.","Effected 9:1 reverse stock split; amended charter and bylaws effective Feb 15, 2024.","Underwriter granted 55,000-share warrant at $7.50 (125% of IPO price), exercisable from Aug 2024 to Feb 2029.","Selling stockholders registered up to 2,969,823 shares for resale; Company receives no proceeds from those sales.","Net proceeds earmarked for CC8464 studies, eye pain/neuropathic pain trials, Phase 2a Erythromelalgia study, spray-formulation development, and promissory note repayment."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-000356","json":"https://secwatch.observer/filing/0001753926-24-000356.json","markdown":"https://secwatch.observer/filing/0001753926-24-000356.md","text":"https://secwatch.observer/filing/0001753926-24-000356.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000356/0001753926-24-000356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000356/g084068_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T21:01:21.600706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18ae2ab026ec9b1551f40a0001f70769c577dd2f","claim":"Pelthos Therapeutics Inc.: Amended and Restated By-laws became effective on February 15, 2024, in connection with the pricing of the Initial Public Offering (effective 2024-02-15).","evidence_excerpt":"On February 15, 2024, the Company’s Amended and Restated By-laws (the “Restated By-laws”) became effective in connection with the pricing of the Initial Public Offering.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000356/0001753926-24-000356-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-02-15"}],"fact_type":"governance_change"},{"claim_id":"c851b101bca759bbe4f47dff8a05c262001d8e8f","claim":"Pelthos Therapeutics Inc.: Filed amended and restated certificate of incorporation effective upon pricing of Initial Public Offering on February 15, 2024, including a 1-for-9 reverse stock split (effective 2024-02-15).","evidence_excerpt":"On February 15, 2024, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the pricing of the Initial Public Offering.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000356/0001753926-24-000356-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-02-15"}],"fact_type":"governance_change"},{"claim_id":"129fc8955cf0bfc47b8793d1c8b7de8c1aa97d82","claim":"Pelthos Therapeutics Inc. entered into Underwriting Agreement with A.G.P./Alliance Global Partners (effective 2024-02-15).","evidence_excerpt":"On February 15, 2024, Chromocell Therapeutics Corporation, a Delaware corporation (the “Company”) entered into an underwriting agreement, as amended by that certain Letter Agreement, dated February 16, 2024 (together, the “Underwriting Agreement”) with A.G.P./Alliance Global Partners, as the representative of the underwriters named therein (the “Representative” or, the “Underwriter”), relating to the issuance and sale by the Company to the Underwriter (the “Initial Public Offering”) of an aggregate of 1,100,000 shares (the “Shares”) of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000356/0001753926-24-000356-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Effective","value":"2024-02-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}